AIDS - Related Cancer – Pipeline Review, H1 2012

Document Sample
AIDS - Related Cancer – Pipeline Review, H1 2012 Powered By Docstoc
					        AIDS - Related Cancer – Pipeline Review, H1 2012


                                                                                          Reference Code: GMDHC1924IDB
                                                                                              Publication Date: April 2012




AIDS - Related Cancer – Pipeline Review, H1 2012                                              GMDHC1924IDB / Pub April 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                             Page(1)
AIDS - Related Cancer – Pipeline Review, H1 2012




Table of Contents
Table of Contents ............................................................................................................................................................................... 2
    List of Tables ................................................................................................................................................................................. 7
    List of Figures ................................................................................................................................................................................ 8
Introduction......................................................................................................................................................................................... 9
    Global Markets Direct Report Coverage ........................................................................................................................................ 9
AIDS - Related Cancer Overview ..................................................................................................................................................... 10
Therapeutics Development............................................................................................................................................................... 11
    An Overview of Pipeline Products for AIDS - Related Cancer ..................................................................................................... 11
AIDS - Related Cancer Therapeutics under Development by Companies ....................................................................................... 13
AIDS - Related Cancer Therapeutics under Investigation by Universities/Institutes......................................................................... 14
Mid Clinical Stage Products.............................................................................................................................................................. 16
    Comparative Analysis .................................................................................................................................................................. 16
Early Clinical Stage Products ........................................................................................................................................................... 17
    Comparative Analysis .................................................................................................................................................................. 17
Pre-Clinical Stage Products.............................................................................................................................................................. 18
    Comparative Analysis .................................................................................................................................................................. 18
AIDS - Related Cancer Therapeutics – Products under Development by Companies ..................................................................... 19
AIDS - Related Cancer Therapeutics – Products under Investigation by Universities/Institutes....................................................... 20
Companies Involved in AIDS - Related Cancer Therapeutics Development .................................................................................... 23
    Aphios Corporation ...................................................................................................................................................................... 23
    PTC Therapeutics, Inc. ................................................................................................................................................................ 24
AIDS - Related Cancer – Therapeutics Assessment ........................................................................................................................ 25
    Assessment by Monotherapy Products ....................................................................................................................................... 25
    Assessment by Combination Products ........................................................................................................................................ 26
    Assessment by Route of Administration ...................................................................................................................................... 27
    Assessment by Molecule Type .................................................................................................................................................... 29
Drug Profiles..................................................................................................................................................................................... 31
    Dermos - Drug Profile .................................................................................................................................................................. 31
         Product Description................................................................................................................................................................. 31
         Mechanism of Action ............................................................................................................................................................... 31
         R&D Progress ......................................................................................................................................................................... 31
    PTC299 - Drug Profile ................................................................................................................................................................. 32
         Product Description................................................................................................................................................................. 32
         Mechanism of Action ............................................................................................................................................................... 32
         R&D Progress ......................................................................................................................................................................... 32
    Doxil + Methotrexate + Prednisone + Vincristine Sulfate + Sargramostim - Drug Profile ............................................................ 34
         Product Description................................................................................................................................................................. 34
         Mechanism of Action ............................................................................................................................................................... 34
         R&D Progress ......................................................................................................................................................................... 34
    Rapamycin - Drug Profile ............................................................................................................................................................ 36
         Product Description................................................................................................................................................................. 36
         Mechanism of Action ............................................................................................................................................................... 36



AIDS - Related Cancer – Pipeline Review, H1 2012                                                                                                   GMDHC1924IDB / Pub April 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                   Page(2)
AIDS - Related Cancer – Pipeline Review, H1 2012




        R&D Progress ......................................................................................................................................................................... 36
    Bevacizumab - Drug Profile ......................................................................................................................................................... 37
        Product Description................................................................................................................................................................. 37
        Mechanism of Action ............................................................................................................................................................... 37
        R&D Progress ......................................................................................................................................................................... 37
    Cetuximab + Fluoroucacil + Cisplatin + Radiation Therapy - Drug Profile ................................................................................... 38
        Product Description................................................................................................................................................................. 38
        Mechanism of Action ............................................................................................................................................................... 38
        R&D Progress ......................................................................................................................................................................... 38
    Gleevec - Drug Profile ................................................................................................................................................................. 40
        Product Description................................................................................................................................................................. 40
        Mechanism of Action ............................................................................................................................................................... 40
        R&D Progress ......................................................................................................................................................................... 40
    SU5416 - Drug Profile ................................................................................................................................................................. 41
        Product Description................................................................................................................................................................. 41
        Mechanism of Action ............................................................................................................................................................... 41
        R&D Progress ......................................................................................................................................................................... 41
    cART + R-EPOCH - Drug Profile ................................................................................................................................................. 42
        Product Description................................................................................................................................................................. 42
        Mechanism of Action ............................................................................................................................................................... 42
        R&D Progress ......................................................................................................................................................................... 43
    Interferon Alfa-2b + Didanosine - Drug Profile ............................................................................................................................. 44
        Product Description................................................................................................................................................................. 44
        Mechanism of Action ............................................................................................................................................................... 44
        R&D Progress ......................................................................................................................................................................... 44
    G-CSF + Cyclophosphamide + Etoposide + Lomustine + Procarbazine + Radiation Therapy - Drug Profile .............................. 45
        Product Description................................................................................................................................................................. 45
        Mechanism of Action ............................................................................................................................................................... 45
        R&D Progress ......................................................................................................................................................................... 46
    Bortezomib - Drug Profile ............................................................................................................................................................ 47
        Product Description................................................................................................................................................................. 47
        Mechanism of Action ............................................................................................................................................................... 47
        R&D Progress ......................................................................................................................................................................... 47
    Lenalidomide - Drug Profile ......................................................................................................................................................... 48
        Product Description................................................................................................................................................................. 48
        Mechanism of Action ............................................................................................................................................................... 48
        R&D Progress ......................................................................................................................................................................... 48
    Lenalidomide - Drug Profile ......................................................................................................................................................... 49
        Product Description................................................................................................................................................................. 49
        Mechanism of Action ............................................................................................................................................................... 49
        R&D Progress ......................................................................................................................................................................... 49
    Liposomal Doxorubicin - Drug Profile .......................................................................................................................................... 50
        Product Description................................................................................................................................................................. 50
        Mechanism of Action ............................................................................................................................................................... 50


AIDS - Related Cancer – Pipeline Review, H1 2012                                                                                              GMDHC1924IDB / Pub April 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                              Page(3)
AIDS - Related Cancer – Pipeline Review, H1 2012




        R&D Progress ......................................................................................................................................................................... 50
    Liposomal Doxorubicin + Bleomycin + Vincristine + Filgrastim - Drug Profile.............................................................................. 52
        Product Description................................................................................................................................................................. 52
        Mechanism of Action ............................................................................................................................................................... 52
        R&D Progress ......................................................................................................................................................................... 52
    Methotrexate + Zidovudine + Radiation Therapy - Drug Profile ................................................................................................... 54
        Product Description................................................................................................................................................................. 54
        Mechanism of Action ............................................................................................................................................................... 54
        R&D Progress ......................................................................................................................................................................... 54
    Halofuginone Hydrobromide - Drug Profile .................................................................................................................................. 55
        Product Description................................................................................................................................................................. 55
        Mechanism of Action ............................................................................................................................................................... 55
        R&D Progress ......................................................................................................................................................................... 55
    Filgrastim + Cyclophosphamide + Cytarabine + Methotrexate + Pegylated Liposomal Doxorubicin Hydrochloride + Prednisone +
    Vincristine Sulfate + Radiation Therapy - Drug Profile ................................................................................................................ 56
        Product Description................................................................................................................................................................. 56
        Mechanism of Action ............................................................................................................................................................... 56
        R&D Progress ......................................................................................................................................................................... 57
    MEAM + HAART + Stem Cell Transplantation - Drug Profile ...................................................................................................... 59
        Product Description................................................................................................................................................................. 59
        Mechanism of Action ............................................................................................................................................................... 59
        R&D Progress ......................................................................................................................................................................... 60
    BCNU + Etoposide + Cytarabine + Melphalan + Autologous Hematopoietic Cell Transplantation - Drug Profile ........................ 61
        Product Description................................................................................................................................................................. 61
        Mechanism of Action ............................................................................................................................................................... 61
        R&D Progress ......................................................................................................................................................................... 61
    Interferon alfa-2b + Zidovudine + Sargramostim - Drug Profile ................................................................................................... 63
        Product Description................................................................................................................................................................. 63
        Mechanism of Action ............................................................................................................................................................... 63
        R&D Progress ......................................................................................................................................................................... 63
    Interferon alfa-n1 + Zidovudine - Drug Profile.............................................................................................................................. 65
        Product Description................................................................................................................................................................. 65
        Mechanism of Action ............................................................................................................................................................... 65
        R&D Progress ......................................................................................................................................................................... 65
    Interferon beta-1b + Zidovudine - Drug Profile ............................................................................................................................ 66
        Product Description................................................................................................................................................................. 66
        Mechanism of Action ............................................................................................................................................................... 66
        R&D Progress ......................................................................................................................................................................... 66
    EPOCH Regimen + Methotrexate + Prednisone + Cytarabine + Filgrastim - Drug Profile .......................................................... 67
        Product Description................................................................................................................................................................. 67
        Mechanism of Action ............................................................................................................................................................... 68
        R&D Progress ......................................................................................................................................................................... 69
    EPOCH Regimen + Methotrexate + Prednisone + Cytarabine + Filgrastim - Drug Profile .......................................................... 71
        Product Description................................................................................................................................................................. 71



AIDS - Related Cancer – Pipeline Review, H1 2012                                                                                              GMDHC1924IDB / Pub April 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                              Page(4)
AIDS - Related Cancer – Pipeline Review, H1 2012




        Mechanism of Action ............................................................................................................................................................... 72
        R&D Progress ......................................................................................................................................................................... 73
    Filgrastim + Pegfilgrastim + Rituximab + Cyclophosphamide + Cytarabine + Doxorubicin Hydrochloride + Etoposide +
    Ifosfamide + Leucovorin Calcium + Liposomal Cytarabine + Methotrexate + Therapeutic Hydrocortisone + Vincristine Sulfate -
    Drug Profile.................................................................................................................................................................................. 75
        Product Description................................................................................................................................................................. 75
        Mechanism of Action ............................................................................................................................................................... 76
        R&D Progress ......................................................................................................................................................................... 77
    Bleomycin Sulfate + Vincristine Sulfate + Doxorubicin Hydrochloride + Zidovudine - Drug Profile.............................................. 79
        Product Description................................................................................................................................................................. 79
        Mechanism of Action ............................................................................................................................................................... 79
        R&D Progress ..................................................................
				
DOCUMENT INFO
Description: AIDS - Related Cancer - Pipeline Review, H1 2012', provides an overview of the AIDS - Related Cancer therapeutic pipeline. This report provides information on the therapeutic development for AIDS - Related Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for AIDS - Related Cancer. 'AIDS - Related Cancer - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
BUY THIS DOCUMENT NOW PRICE: $500 100% MONEY BACK GUARANTEED
PARTNER GlobalMarketsDirect
Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. Global Markets Direct has a broad range of coverage over key market segments. It has a global scope, covering a broad range of countries constituting more than 90% of global revenues in each of the industries it covers. With a large dedicated research and analysis capability, Global Markets Direct employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries